Annotation Detail
Information
- Associated Genes
- BRAF
- Associated Variants
-
BRAF V600E AMPLIFICATION
(
ENST00000288602.11 )
BRAF V600E AMPLIFICATION ( ENST00000288602.11 ) - Associated Disease
- colorectal cancer
- Source Database
- CIViC Evidence
- Description
- Paired pre-treatment and post-progression tumor biopsies from BRAF-mutant CRC patients treated with RAF inhibitor combinations were analyzed. Alterations in MAPK pathway genes were found in resistant tumors not present in matched pre-treatment tumors, including KRAS amplification, BRAF amplification, and a MEK1 mutation.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/2929
- Gene URL
- https://civic.genome.wustl.edu/links/genes/5
- Variant URL
- https://civic.genome.wustl.edu/links/variants/1269
- Rating
- 3
- Evidence Type
- Predictive
- Disease
- Colorectal Cancer
- Evidence Direction
- Supports
- Drug
- Dabrafenib,Panitumumab
- Evidence Level
- C
- Clinical Significance
- Resistance
- Pubmed
- 25673644
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Dabrafenib | Resitance or Non-Reponse | true |
| Panitumumab | Resitance or Non-Reponse | true |